Safety and Efficacy of House Dust Mite Allergen Extract in the Treatment of Allergic Rhinoconjunctivitis

Phase 4CompletedNCT00263549

Allergopharma GmbH & Co. KG

Overview

The trial is performed to assess efficacy and safety of Novo-Helisen Depot in allergic Rhinoconjunctivitis

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

House Dust Mite Allergy

Interventions

House dust mite Novo Helisen DepotBIOLOGICAL

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Positive skin prick test to house dust mite, * Positive RAST test to house dust mite, * Positive provocation test result to house dust mite, Exclusion Criteria: * Serious chronic diseases, * Other perennial allergies

Locations (1)

Allergopharma GmbH & Co. KG

Reinbek, Germany

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.